1361644-26-9
基本信息
Aldoxorubicin (INNO-206)
Aldoxorubicin Aldoxorubicin
N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide
1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, (2E)-2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
(E)-N’-[1-[(2S,4S)-4-[[(2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-2-tetrahydropyranyl]oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-2-tetracenyl]-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1-pyrrolyl)hexanehydrazide
物理化学性质
密度 | 1.60±0.1 g/cm3(Predicted) |
储存条件 | -80°, stored under nitrogen,unstable in solution, ready to use. |
溶解度 | DMSO : 75 mg/mL (99.90 mM) |
酸度系数(pKa) | 7.36±0.60(Predicted) |
形态 | Solid |
颜色 | Purple to purplish red |
安全数据
危险性符号(GHS) | GHS08 |
警示词 | 危险 |
危险性描述 | H340-H350-H360 |
ALDOXORUBICIN价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/11/08 | HY-16261 | ALDOXORUBICIN Aldoxorubicin | 1361644-26-9 | 2mg | 750元 |
2024/11/08 | HY-16261 | ALDOXORUBICIN Aldoxorubicin | 1361644-26-9 | 5mg | 1200元 |
2024/11/08 | HY-16261 | ALDOXORUBICIN Aldoxorubicin | 1361644-26-9 | 10mg | 1740元 |
常见问题列表
Topoisomerase II
|
Daunorubicins/Doxorubicins
|
Aldoxorubicin (INNO-206) (0.27 to 2.16 μM) inhibits blood vessel formation and reduces multiple myeloma cell growth in a pH-dependent fashion.
Aldoxorubicin (INNO-206) (10.8 mg/kg, i.v.) shows significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAGκ-1A tumor. Aldoxorubicin (INNO-206) shows a good safety profile at doses up to 260 mg/mL doxorubicin equivalents, and is able to induce tumor regressions in breast cancer, small cell lung cancer and sarcoma in phase I study. Aldoxorubicin (INNO-206) shows superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models.